Tetra Bio-Pharma files new drug submission for Reduvo in Canada

Tetra Bio-Pharma

30 December 2020 - The addressable market is estimated to be $80 million CDN by 2022.

Tetra Bio-Pharma announced today that the new drug submission for the dronabinol soft gel capsules, has been filed with Health Canada. 

If successful, it will provide Tetra with its first drug identification number for a THC-based prescription drug.

Read Tetra Bio-Pharma press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Canada , Dossier